Fair Value Measurements - Additional Information (Detail)	3 Months Ended		12 Months Ended
	Dec. 31, 2015 USD ($) shares	Dec. 31, 2014 USD ($)	Sep. 30, 2011 shares	Sep. 30, 2015 USD ($)	Jan. 31, 2013 shares	Dec. 31, 2012 shares	Jun. 30, 2010 shares
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short term investments | $	$ 14,431,498			$ 17,539,902
Fair value of investment | $	$ 14,271,893			$ 17,234,960
Warrants outstanding	1,466,437
Non-cash gain (loss) from change in fair value of the derivative liability | $	$ (21,574)	$ 2,179,651
Ablaris Therapeutics
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants outstanding	500,000
Non-cash gain (loss) from change in fair value of the derivative liability | $	$ (1,950)	$ 202,491
Duration of exchange rights	7 years
Exchange right convertible conversion ratio for first year	0.06
Exchange right convertible conversion ratio for second year	0.04
Exchange right convertible conversion ratio for third year	0.03
Exchange right convertible conversion ratio for fourth year	0.02
Exchange right convertible conversion ratio for fifth year and beyond	0.01
Number of exchange right sold			675,000
2010 Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants issued to acquire Common Stock							329,649
Warrants expired	24,324
2012 Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants issued to acquire Common Stock						912,543
Warrants outstanding	265,161
2013 Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants issued to acquire Common Stock					833,530
Warrants outstanding	12,123